Clinical Trials
13 trialsNCT04897321 2026-05-19
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT04901702 2026-05-19
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT04851119 2026-05-05
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
Phase 1/2 Recruiting
NCT04478292 2026-05-04
A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy
Shanghai Children's Medical Center
Phase 3 Recruiting
NCT04308330 2026-04-15
NYMC195
New York Medical College
Phase 1 Recruiting
NCT06638931 2026-04-15
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT01804634 2026-03-13
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT04928677 2026-02-17
A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT07148050 2026-02-17
IMPACT
Seattle Children's Hospital
Phase 1 Recruiting
NCT07300449 2025-12-23
A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and Adolescents
Sun Yat-sen University
Phase 2 Recruiting
NCT06198296 2025-11-03
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Baylor College of Medicine
Phase 1 Recruiting
NCT07188311 2025-09-23
Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in Children
Sun Yat-sen University
Phase NA Recruiting
NCT04634357 2025-04-09
ARYA-2
Eureka Therapeutics Inc.
Phase 1/2 Recruiting